SCHEMBL17255348

SCHEMBL17255348

COc1ccc(-c2cc(-c3nc4cc(F)c(Cl)cc4[nH]3)[nH]n2)c(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 5/20 0.57
PDPK1 O15530 1/20 0.43
MEN1 O00255 6/20 0.42
KMT2A Q03164 6/20 0.42
ALOX15 P16050 3/20 0.42
NPC1 O15118 7/20 0.41
RAB9A P51151 7/20 0.41
PRKAG1 P54619 2/20 0.40
PRKAA1 Q13131 2/20 0.40
PRKAB1 Q9Y478 2/20 0.40
USP2 O75604 1/20 0.39
DGAT1 O75907 1/20 0.38
FOXO1 Q12778 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17255260 0.95 AMY1A (0.58) AMY1APDPK1MEN1KMT2AALOX15
SCHEMBL17255182 0.88 AMY1A (0.60) AMY1APDPK1MEN1KMT2AALOX15
SCHEMBL17255215 0.88 AMY1A (0.50) AMY1APDPK1MEN1KMT2AALOX15
SCHEMBL17255147 0.88 AMY1A (0.61) AMY1APDPK1MEN1KMT2AALOX15
SCHEMBL17255144 0.85 AMY1A (0.60) AMY1APDPK1MEN1KMT2AALOX15
SCHEMBL17255178 0.84 AMY1A (0.55) AMY1APDPK1MEN1KMT2ANPC1
SCHEMBL17255253 0.83 ALPL (0.46) AMY1APDPK1MEN1KMT2AALOX15
SCHEMBL17255158 0.83 RAB9A (0.52) AMY1APDPK1MEN1KMT2AALOX15
SCHEMBL17255248 0.82 AMY1A (0.53) AMY1APDPK1MEN1KMT2AALOX15
SCHEMBL17255340 0.81 AMY1A (0.53) AMY1APDPK1MEN1KMT2AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150329527-A1 PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-11-19 US claimed
EP-2944635-A1 PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2015-11-18 EP claimed
US-9951049-B2 Pyrazole linked benzimidazole conjugates and a process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-04-24 US disclosed
US-9951049-B2 Pyrazole linked benzimidazole conjugates and a process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-04-24 US disclosed
US-20150329527-A1 PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-11-19 US disclosed
US-20150329527-A1 PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-11-19 US disclosed
EP-2944635-A1 PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2015-11-18 EP disclosed
EP-2944635-A1 PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2015-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329527-A1 PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF BRDT, MCL1, MGST3 AMY1A 4542/4885PDPK1 1052/4885MEN1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.